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To maintain intestinal health, the immune system must faithfully
respond to antigens from pathogenic microbes while limiting re-
actions to self-molecules. The gastrointestinal tract represents
a unique challenge to the immune system, as it is permanently
colonized by a diverse amalgam of bacterial phylotypes producing
multitudes of foreign microbial products. Evidence from human
and animal studies indicates that inflammatory bowel disease
results from uncontrolled inflammation to the intestinal micro-
biota. However, molecular mechanisms that actively promote mu-
cosal tolerance to themicrobiota remain unknown.We report herein
that a prominent human commensal, Bacteroides fragilis, directs the
development of Foxp3+ regulatory T cells (Tregs) with a unique “in-
ducible” genetic signature. Monocolonization of germ-free animals
with B. fragilis increases the suppressive capacity of Tregs and indu-
ces anti-inflammatory cytokine production exclusively from Foxp3+
T cells in the gut. We show that the immunomodulatory molecule,
polysaccharide A (PSA), of B. fragilis mediates the conversion of
CD4+ T cells into Foxp3+ Treg cells that produce IL-10 during commen-
sal colonization. Functional Foxp3+ Treg cells are also produced by
PSA during intestinal inflammation, and Toll-like receptor 2 signaling
is required for both Treg induction and IL-10 expression. Most signi-
ficantly, we show that PSA is not only able to prevent, but also cure
experimental colitis in animals. Our results therefore demonstrate
that B. fragilis co-opts the Treg lineage differentiation pathway in
the gut to actively induce mucosal tolerance.
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Bacteria colonize almost every environmentally exposed sur-face of the human body, with the greatest quantity and di-
versity found in the lower gastrointestinal tract (1). One-hundred
trillion bacteria representing hundreds of species live in ho-
meostasis with the intestinal immune system. Maintenance of
homeostasis toward the intestinal microbial milieu is critical to
the preservation of health (2). Defects in mucosal tolerance lead
to disorders, such as inflammatory bowel disease (IBD); Crohn
disease and ulcerative colitis are idiopathic human syndromes
marked by unrestrained gastrointestinal inflammation. In the
United States alone, over 1 million people suffer from IBD,
making it a serious social and medical problem. Additionally, the
overall rates of diagnosis are increasing and the mean age of
onset is decreasing. Although the causes for IBD remain enig-
matic, interactions between host genetics, the immune system,
and the intestinal microbiota appear to be central to the deve-
lopment and severity of disease. A growing body of evidence
suggests that a breakdown in immune tolerance to the micro-
biota is a critical event in the onset and progression of IBD.
Indeed, IBD patients have increased reactivity to antigens of the
normal microbiota and antibiotics offer some therapeutic bene-
fits. Furthermore, germ-free animals do not develop experimen-
tal colitis and the microbial community of the gut is significantly
altered in IBD patients (2, 3). The microbiota and the mucosal
immune system appear to have forged an intricate evolutionary
relationship with important implications for human health, and
disturbances in our partnership with symbiotic bacteria may be
a risk factor for IBD.
Intestinal immune health is achieved, in part, through the de-
velopment of opposing arms of the adaptive immune response.
Induction of a proinflammatory T-cell response by microor-
ganisms can elicit development of either T-helper-1 (Th1), Th2,
or Th17 cells (4). Proinflammatory T-cell responses are sup-
pressed by the action of various subsets of regulatory T cells
(Tregs). Naturally occurring Tregs emerge from the thymus and
are marked by expression of CD4, CD25, and the transcription
factor Foxp3 (Forkhead Box transcription factor for Treg differ-
entiation) (5). More recent studies have provided evidence that
other populations of Tregs exist that have variable expression of
Foxp3 and secrete anti-inflammatory cytokines, such as IL-10 (6).
These Treg subsets, often referred to as “inducible Tregs,” are not
found in the thymic environment but, rather, seem to be induced
in peripheral tissues, such as the gut. Suppression of Th1 and
Th17 cell responses by Tregs prevents inflammation in experi-
mental models of colitis (7, 8). Emerging studies have highlighted
a key role for the commensal microbiota in the development of
intestinal Th17 cells. Germ-free mice display very low numbers of
Th17 cells within the lamina propria that is restored upon colo-
nization with a complex microbial consortium (9–11) or even
specific bacterial species (12, 13). Studies have also shown that
germ-free animals are altered in Treg proportions of the gut (10,
14). Thus, the microbiota plays an active role in the development
and function of both pro- and anti-inflammatory T-cell pathways.
However, microbial molecules that coordinate the Treg/Th17 axis
remain to be described.
Polysaccharide A (PSA), produced by the human symbiont
Bacteroides fragilis, is able to protect animals from intestinal in-
flammation by suppressing IL-17 production (15). We report here
that colonization of germ-free animals withB. fragilismediates the
development of inducible Tregs with a unique genetic signature.
CD4+Foxp3+ Tregs that produce IL-10 differentiate in the gut,
but not in systemic compartments in response to PSA. Natural
Treg subsets are not affected by B. fragilis colonization. PSA
engenders mucosal tolerance by promoting the differentiation
of functional Treg cells during homeostasis and intestinal in-
flammation. Toll-like receptor 2 (TLR2) signaling is required for
induction of Foxp3+ Tregs and IL-10 production by PSA, and
TLR2−/− animals treated with PSA are not protected from colitis.
Finally, we show that PSA is capable of reversing experimental
colitis in animals, thus representing a potentially unique and nat-
ural therapy for human IBD. Our findings support recent specu-
lation that Foxp3+ Treg cells respond to commensal microbial
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antigens (16, 17), and define the cellular and molecular pathway
by which PSA functions to control intestinal inflammatory disease.
Results
Bacteroides fragilis Colonization Elicits Mucosal Tolerance. The micro-
biota has profound influences on the development and function of
the immune system (2). Colonization of germ-free animals with
B. fragilis represents a model system for the study of immune-
bacterial symbiosis. Because recent reports have revealed a critical
role for Treg-produced IL-10 during maintenance of intestinal
homeostasis, we sought to understand how B. fragilis colonization
directly affects Treg development (18). Germ-free C57BL/6 mice
were lethally irradiated and reconstituted with bone marrow
from Foxp3-GFP mice. Mice were either left germ-free or mono-
associated with WT B. fragilis or a strain deleted of PSA (B. fragi-
lisΔPSA) (Fig. S1). Consistent with recent reports (9, 10), the
percentage of Treg cells (CD4+Foxp3+) residing within either the
mesenteric lymph node (MLN) or colon did not differ significantly
between groups (Fig. S2A and B), suggesting that the microbiota is
not a requirement for the presence of naturally occurring Tregs
cells. Remarkably, production of IL-10 within the intestine is de-
ficient in the absence of themicrobiota (compare conventional with
germ-free mice); moreover, B. fragilis colonization restores the
production of IL-10 within the colon in a PSA-dependent manner
(Fig. 1A). Monoassociation of germ-free animals with B. fragilis
results in a 2-fold increase in the percentage of IL-10–producing
Foxp3+ Tregs within the colon (Fig. S3A). The induction of IL-10
fromFoxp3+ cells byB. fragilis completely requires PSA, as Tregs in
B. fragilisΔPSA-colonized animals have similar IL-10 levels as
germ-free mice (Fig. 1B). Colonization with B. fragilis directs IL-10
production almost exclusively from Foxp3+ (and not Foxp3−)
T cells (Fig. 1B). Compared with conventionally-colonized animals,
purified CD4+Foxp3+ Tregs from germ-free mice display lower
expression of IL-10, and the Treg-associated cytokine TGF-β2
(Fig. 1C and Fig. S3B). B. fragilis monoassociation restores ex-
pression of these anti-inflammatory genes, a phenotype that is
completely dependent on PSA production. Microbial colonization
does not affect all Treg-associated genes, as CD25 expression does
not change in all groups tested (Fig. S3B). Thus, homeostatic mi-
crobial colonization by B. fragilis has a dramatic impact on the
programming of CD4+Foxp3+ Tregs in the colon.
We wanted to examine whether PSA is able to convert Foxp3+
T cells from Foxp3− precursors. CD4+Foxp3− T cells were pu-
rified from Foxp3-GFP animals (19) and adoptively transferred
into germ-free Rag−/− mice. Groups of animals were either left
germ-free or colonized with WT or B. fragilisΔPSA bacteria.
Three weeks posttransfer, CD4+ T cells were analyzed for the
expression of Foxp3 and IL-10. Fig. 1D shows that although
germ-free animals have few CD4+ T cells that expressed Foxp3,
animals colonized with WT B. fragilis contained significant levels
of converted Foxp3+ Tregs (statistical analysis in Fig. S3C).
Conversion to Foxp3 expression was dependent on PSA, as B.
fragilisΔPSA-colonized animals contained cell levels comparable
to germ-free animals (Fig. 1D). Remarkably, Foxp3+ T cells
from B. fragilis-colonized animals acquired IL-10 expression (Fig.
1E). These results identify a unique bacterial molecule of the
intestinal microbiota that is able to promote lineage differenti-
ation of Foxp3+ Treg cells.
PSA Promotes Inducible Foxp3+ Tregs with Suppressive Activity. We
orally administered PSA to mice and monitored the CD4+
CD25+Foxp3+ population of Tregs in theMLN.Mice treated with
PSA displayed increased percentages of CD4+Foxp3+ T cells
comparedwith controlmice (Fig. 2A). One of the primary functions
of Treg cells is to suppress the activation and proliferation of in-
flammatory effector T cells (Teffs). The suppressive properties of
Tregs following PSA administration were determined by the ad-
dition of varying ratios of CD4+CD25+ T cells purified fromMLNs
to naive responder cells. Tregs isolated from PSA-treated animals
have increased suppressive capacity compared with PBS-treated
control animals (28.5% proliferating responder cells vs. 43.0% at
a 1:2 Treg:Teff ratio) (Fig. 2B). These findings demonstrate that
PSA induces the differentiation of functional Foxp3+ Tregs with
enhanced suppressive activity.
Various subsets of Tregs exist within the Foxp3+ and Foxp3−T-
cell populations; therefore, we analyzed the expression of Treg-
associated genes to understand how PSA affects the development
of Foxp3+ Tregs. Foxp3-GFP mice were gavaged with purified
PSA (or PBS control), and RNA was extracted from either
CD4+Foxp3− or CD4+Foxp3+ T cells from the MLNs following
cell purification. As expected, gene expression in Foxp3− and
Foxp3+ T-cell subsets differed dramatically and included higher
basal levels of IL-10, TGF-β2, GITR (glucocorticoid-induced
TNF-related protein), ICOS, CTLA-4, and Ebi3 (subunit of IL-
35) in Foxp3+ T cells (Fig. 2C and Fig. S4). Remarkably, PSA
induces over 8-fold increased levels of IL-10 from CD4+Foxp3+
Tregs than that expressed in PBS-treated cells, and had virtually
no impact on CD4+Foxp3− T cells. Accordingly, although TGF-
β2 expression in CD4+Foxp3− T cells was not altered, PSA eli-
cited significant induction of TGF-β2 from Foxp3+ Treg cells.
Although Treg subsets that do not express Foxp3 have been de-
scribed based on IL-10 and TGF-β production (Tr1 and Th3 cells,
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Fig. 1. Bacteroides fragilis colonization elicits tolerant T cell responses in
the intestine. (A) Germ-free C57BL/6 mice were reconstituted with Foxp3-
GFP bone marrow and colonized with bacteria as indicated (Conv. refers to
specific pathogen-free conventional mice). RNA was extracted from the
colons of mice and IL-10 measured by qRT-PCR. Each symbol indicates an
individual mouse. *P < 0.05; **P < 0.01. These data are representative of two
independent trials with at least three mice in each group. (B) Lamina propria
lymphocytes were assessed for IL-10 from CD4+Foxp3+ and CD4+Foxp3−
subsets by flow cytometry (FC). These data are representative of three in-
dependent trials. (C) Cells from the MLNs of mice were purified to isolate
CD4+Foxp3-GFP T cells. RNA was extracted and the IL-10 transcript levels
analyzed by qRT-PCR. Cell populations were >99% pure. Error bars indicate
SD from samples run in triplicate from the same experiment. These data are
representative of two independent trials with at least four mice per group.
(D and E) Germ-free C57BL/6 Rag−/− animals were sublethally irradiated and
CD4+Foxp3− T cells transferred from Foxp3-GFP donor mice. Cell purity was
always >99%. Animals were either left germ-free or colonized with in-
dicated bacterial strains. Foxp3 was analyzed by GFP expression in D and
IL-10 in E. (E) The percentage of IL-10+ cells within the CD4+Foxp3+ converted
subset. These data are representative of two independent trials with at least
three mice in each group.
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respectively) (20), PSA’s effects are restricted to the Foxp3+ Treg
population. PSA treatment also significantly increases the tran-
scription of granzyme B, perforin, and CCR6 (a chemokine re-
ceptor associated with the migration of Treg cells) from Foxp3+
Tregs (Fig. 2C and Fig. S4). It is important to note that PSA does
not globally impact all Treg-derived cytokines, as expression of
TGF-β1 and Ebi3 are not altered, demonstrating specificity for
a distinct Treg profile. Furthermore, production of the natural
Treg-associated surface receptors CTLA-4, GITR, and ICOS are
not changed among Foxp3+ cells in response to PSA treatment
(Fig. 2C and Fig. S4). Taken together, these data reveal that PSA
activates inducible Foxp3+ Tregs and identifies a “PSA-specific”
gene expression program within Foxp3+ Treg cells.
We have previously reported that colonization of germ-free ani-
mals with PSA-producing bacteria induces production of the Th1
cytokine IFN-γ among splenic CD4+ T cells (21). To further in-
vestigate the lineage differentiation of immune cells directed by
PSA, we examined animals for IFN-γ expression among Foxp3+
T cells. Intriguingly, IFN-γ expression in the MLNs is found exclu-
sively in the Foxp3− subset and is not affected by microbial coloni-
zation (Fig. S5). Furthermore, splenic CD4+ T cells produce IFN-γ
only from Foxp3−/IL-10− T cells that is dependent on PSA expres-
sion (Fig. S6). These results demonstrate that there is a compart-
mental difference in the ability of PSA to induce a Th1 profile in the
spleen, although promoting a tolerogenic immune environment in
the gut consisting of CD4+Foxp3+IFN-γ− Treg cells.
PSA Activity Requires TLR2 Signaling. Many microbial products are
sensed by pattern recognition receptors, such as TLRs. Although
historically believed to induce inflammation, a series of studies
now show that TLR signaling can also promote anti-inflammatory
responses (reviewed in ref. 22). PSA has been shown to coordinate
cytokine production from innate immune cells through TLR2 sig-
naling (23); however, a role for TLR2 inTreg development remains
uncertain. To understand the mechanism by which PSA promotes
Tregs, TLR2-deficient animals were orally treated with PSA and
analyzed for CD4+Foxp3+ T-cell development. In contrast to the
Treg expansion seen in WT animals (see Fig. 2A), we observed no
difference in the percentage of CD4+Foxp3+ T cells in TLR2−/−
mice treated with PSA compared with PBS controls (Fig. 2D).
Additionally, induction of IL-10 by Tregs (CD4+CD25+) in re-
sponse to PSA is lost in the absence of TLR2 expression (Fig. 2E).
Our findings are entirely consistent with reports that TLR2−/−mice
have defects in Foxp3+ Treg cells (24, 25). Although further work is
needed to fully understand how innate immune signaling contrib-
utes to Treg lineage differentiation, PSA-mediated Treg develop-
ment is a TLR2-dependent mechanism.
PSA Expands Functional Foxp3+ Tregs During Protection from Experi-
mental Colitis.Activation of innate and adaptive immune cells and
secretion of inflammatory cytokines are not found under steady
state conditions within the intestine. We next wished to examine
Foxp3+ Treg cell development during intestinal disease. TNBS
(2,4,6-trinitrobenzene sulfonic acid) treatment of animals results in
gut inflammation, which activates T-cell responses; animals lose
a significant amount of weight and displaymarked thickening of the
colon, with lymphocyte infiltration and concomitant epithelial hy-
perplasia (26). As previously reported, disease was not evident in
TNBS-treated animals that were treated with purified PSA (15).
Vehicle treated (PBS; −TNBS) and PBS treated TNBS animals
(TNBS+PBS) had a similar percentage of Foxp3+Treg cells within
the CD4+CD25+ T cells of the MLN (Fig. 3A). Consistent with
PSA’s anti-inflammatory properties, mice given PSA reproducibly
had a 5 to 10% increase in the percentage of Foxp3+ cells within the
CD4+CD25+ compartment of the MLNs (Fig. 3A). Additionally,
the absolutenumberofCD4+CD25+Foxp3+ cells in theMLNswas
significantly higher in PSA-treated mice compared with PBS or
noncolitic animals (Fig. 3B). PSA expansion of the Foxp3+ Treg
population is specific, as the percentage of B cells in the MLNs
did not differ between PBS and PSA fed mice (Fig. S7). Consis-
tent with an increase in the percentage of Foxp3+ cells in PSA-
treated mice, there was an increase in the expression of the foxp3
transcript in MLNs (Fig. 3C). Furthermore, we also found that
the Foxp3 expression was increased on a per cell basis in
CD4+CD25+ cells during PSA-mediated protection from colitis
(Fig. S8), demonstrating that PSA up-regulates proportional and
cell-intrinsic Foxp3 expression. The suppressive capacity of Tregs
during PSA-mediated protection from intestinal inflammation
was determined by in vitro suppression assays. As expected,
proliferation was partially suppressed (proliferation of effector
cells in the absence of Tregs was > than 90%) when Tregs from
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Fig. 2. PSA is sufficient to induce functional Foxp3+ Tregs with an inducible
phenotype. (A) Foxp3-GFP mice were orally gavaged with purified PSA,
MLNs harvested, and cells stained for CD4 and CD25. Each symbol represents
the percent of CD4+ Foxp3-GFP+ cells from a single mouse. Results are rep-
resentative of three independent trials with four mice per group. **P < 0.01.
(B) CD4+CD25+ cells were purified from the MLNs of mice treated with either
PBS or PSA, as indicated in A, and incubated with CFSE-pulsed CD4+CD25−
effector T cells in an in vitro suppression assay. Numbers indicate the per-
centage of cells undergoing at least one cellular division at three different
ratios of effector T cells (Teff) and Tregs. These data are representative of
two independent trials. (C) Foxp3-GFP mice were orally treated with purified
PSA. MLNs were extracted and CD4+Foxp3+ or the CD4+Foxp3− T cells were
purified based on ±GFP expression (purity >99%). RNA was extracted and
used for qRT-PCR. These data are representative of three independent
experiments. Light bars indicated cells derived from PBS treated mice and
dark bars from PSA-treated mice. (D) TLR2−/− mice were orally treated with
PSA. MLNs were extracted and analyzed for the percentage of CD4+Foxp3+
cells. Each symbol in the bar graph represents the percentage of CD4+Foxp3+
from an individual mouse. NS, not significant. Results are representative of
three independent trials with at least three mice per group. (E) CD4+CD25hi+
and CD4+CD25− T cell populations were FACS purified from MLNs of PSA-
treated TLR2−/− mice. IL-10 levels were analyzed by qRT-PCR. Light and dark
bars indicate IL-10 levels in PBS or PSA treated animals, respectively. Error bars
represent the SD from samples of the same experiment run in triplicate.
Results are representative of two independent trials with four mice per group.
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vehicle (PBS;−TNBS) or PBS-treated colitic mice (TNBS+PBS)
were added to the culture (Fig. 3D). Notably however, Tregs
isolated from the MLNs of PSA fed mice (TNBS+PSA) sup-
pressed T-cell proliferation to a significantly higher level than
cells from untreated animals (43.5% proliferating responder cells
vs. 63.5% at a 1:2 Treg:Teff ratio), demonstrating Tregs from
animals protected from colitis by PSA have increased functional
suppressive activity.
PSA Protection from Intestinal Inflammation Requires TLR2.Multiple
studies have implicated TLR signaling by innate immune cells
during inflammatorydisease (27).Furthermore,TLR2signalinghas
been shown to have significant effects on Treg expansion and
function (24, 25). We are therefore in a unique position to examine
how TLR2 responses to a natural microbial ligand affect intestinal
inflammatory disease. WT or TLR2−/− animals were orally treated
with PSAor PBS before induction of TNBS colitis.WTanimals had
ulcerative lesions, lymphocyte infiltration, and thickening of the
intestinal mucosa following administration of TNBS (PBS treat-
ment); WT animals treated with PSA were protected from disease
(Fig. 3E). In contrast, TLR2−/−mice treated with PSA had marked
inflammation including thickening of the mucosa, infiltrating leu-
kocytes, and crypt loss (Fig. 3E). Scoring by a blinded pathologist
revealed that TLR2−/− animals are resistant to PSA-mediated
protection, as no differences in colitis scores were observed for
TLR2-deficient animals (Fig. 3F). As previously reported, WT
animals were protected from colitis by PSA (Fig. 3F) (15). We next
determined the impact of TLR2 signaling on cytokine induction by
PSA in animals. IL-10 expression was induced in response to PSA
during protection from colitis inWT animals (Fig. 3G); however, in
the absence of TLR2 signaling, IL-10 was no longer up-regulated in
PSA-treated animals. Suppression of the proinflammatory cytokine
IL-17 by PSA was evident in WT animals; intriguingly, IL-17 levels
were actually increased in TLR2−/− mice given PSA compared
with PBS consistent with no protection from colitis in the absence
of TLR2 (Fig. 3G). To examine a role for TLR2 in coordination
of Treg responses by PSA, we determined the proportions of
CD4+Foxp3+ Tregs in TLR2−/− animals treated with PSA during
TNBS colitis. As shown in Fig. 3H, there are no differences in the
percentage of Tregs in TLR2−/− animals in response to PSA. These
results demonstrate thatTLR2signalingbyPSA is required forTreg
induction and provide a molecular mechanism for protection from
experimental colitis.
PSA Treatment Cures Animals with Experimental Colitis. Prophylactic
therapies for IBD are unsuitable, as there are no diagnostics that
accurately predict disease development and patients must be
treated after onset of symptoms.We thus sought to investigate the
possibility that PSA would be efficacious for established colitis,
potentiating its application as a treatment for established IBD.
Animals were induced for TNBS colitis, and groups were treated
with PBS before disease induction (TNBS+PBS) or PSA, either
before disease induction (pre-TNBS+PSA) or following rectal
TNBS administration (post-TNBS+PSA). PBS-treated TNBS
animals lost a significant amount of weight (approximately 20%
weight loss) by 8 d (Fig. 4A). PSA treatment 1 d following onset of
intestinal inflammation corrected weight loss equal to or better
than PSA treatment before disease; treatment 2 d after colitis
induction also provided protection (Fig. S9). Animals with colitis
exhibited severe disease 5 d post-TNBS treatment, which was not
seen in animals treated with PSA post-TNBS (Fig. 4B). Using
a standard scoring system, animals treated with TNBS showed
a high degree of disease (Fig. 4C). However, both pre- and
posttreatment with PSA significantly prevented the development
of colitis similarly. Animals administered PSA following the onset
of disease showed increased IL-10 and Foxp3 expression in gut
tissues (Fig. S9), and displayed a significant decrease in IL-17
levels during both protection and cure of colitis (Fig. S10).
Accordingly, the percentage of CD4+CD25+Foxp3+ subset was
significantly increased in PSA-treated animals compared with
diseased animals (Fig. 4D). Rectal administration of high doses of
TNBS causes a severe intestinal immune response that leads to
mortality of animals. Remarkably, animals treated with PSA, even
after the commencement of disease, were dramatically rescued
from death compared with control treated animals (Fig. 4E).
Together our studies reveal that gut bacteria produce molecules
that coordinate the development of inducible Foxp3+ Tregs, and
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Fig. 3. PSA expands functional Foxp3+ Tregs during protection from ex-
perimental colitis. (A) BALB/c mice were treated with PSA or PBS during TNBS
induced colitis and analyzed for the percentage of CD25+Foxp3+ cells within
the CD4+ population of the MLN. These data are representative of three
independent trials with four mice per group. (B) Mice were treated as in A,
MLN cells were counted, and absolute numbers of CD4+CD25+Foxp3+ cells
determined (×103). Numbers represent the average of four mice with error
bars indicting SD, and are representative of three independent trials. (C)
RNA was extracted from the MLNs of mice treated with PSA and foxp3
transcript expression is shown, normalized to β-actin expression in the total
lymph node. Numbers represent the average of four mice, with error
bars indicating SD, and are representative of three independent trials. (D)
CD4+CD25+ cells were purified from the MLNs of colitic PBS or PSA-treated
mice and incubated with CFSE-pulsed CD4+CD25− responder cells in an in
vitro suppression assay. Numbers indicate the percentage of cells under-
going at least one cellular division at two different ratios of Teffs and Tregs.
These data are representative of two independent trials. (E) C57BL/6 WT or
TLR2−/− animals were gavaged with purified PSA (or PBS) before TNBS ad-
ministration. Colons were fixed, sectioned, and H&E stained. Representative
histological sections are shown. (F) Colitis scores show that PSA protects WT
but not TLR2−/− animals from experimental colitis. Each symbol represents
a separate animal, and data are from two independent trails. *P < 0.05. NS,
not significant. (G) RNA was extracted from the MLNs of indicated mice ei-
ther treated with PBS or PSA, and the expression levels of IL-10 and IL-17A
were assayed by qRT-PCR. Relative units are represented as transcript levels
relative to expression of a housekeeping gene (L32). Results are represen-
tative of three independent trials with four mice per group; error bars in-
dicate SD. (H) Percentages of CD4+CD25+Foxp3+ T cells in the MLNs of TLR2−/−
mice treated with PBS or PSA during TNBS induced colitis. Plots are gated on
CD4+ T cells. Results are representative of three independent trials with four
mice per group.
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immunomodulation of Tregs by PSA may represent a unique
approach to engendering mucosal tolerance as a therapy for in-
testinal inflammatory diseases.
Discussion
Tregs represent an important immune mechanism for inducing
tolerance to antigens (both self and foreign) to prevent auto-
immunity and unwanted inflammation. Although there has been
speculation regarding a role for the microbiota in the generation
of various Treg subsets (17), identification of Treg-inducing
molecular signals from gut bacteria have not been described
previously. Here we identify that B. fragilis produces a microbial
molecule that can coordinate the development of an inducible
population of CD4+Foxp3+ Treg cells. PSA of B. fragilis directs
a specific gene-expression profile in functionally suppressive
Tregs. Notably, PSA induces IL-10 and TGF-β2 responses from
Foxp3+ Tregs and not from Foxp3− T-cell subsets. Moreover,
levels of natural Treg markers such as GITR, CD25, and CTLA-
4 are not affected by PSA. We also report that germ-free mice
have a reduction in the levels of IL-10 expression within the
Foxp3+ compartment that is restored upon colonization with
B. fragilis. PSA can convert Foxp3− T cells into a Foxp3+ Tregs
that express IL-10. Foxp3+ Treg induction and IL-10 production
in response to PSA require expression of TLR2. Accordingly,
TLR2-deficient animals are not protected from experimental
colitis by PSA. Although further work is required to understand
the nature of TLR signaling, these results provide a molecular
mechanism for PSA’s anti-inflammatory properties.
Numerous human and animal studies now indicate that IBD
results from a loss of tolerance to commensal bacteria; we show
that PSA directs the development of Tregs during protection and
cure of experimental colitis. These findings are consistent with
studies that show inducible IL-10 production by Foxp3+ T cells is
important for mediating tolerance at mucosal surfaces and pre-
venting intestinal inflammation (18). Accordingly, PSA repre-
sents a unique example of a commensal bacterial molecule that
directs the development and function of inducible Tregs during
health and disease. We propose that gut bacteria are able to
modulate peripheral Treg functions as a mechanism to engender
mucosal tolerance. Collectively, a growing body of evidence now
indicates that the intricate interplay between commensal bacteria
and regulation of the immune system has profound influences on
human health. Conceivably, harnessing the immunomodulatory
potential of PSA may lead to natural biological therapies for
IBD based on novel pathways for Treg induction.
Materials and Methods
Animals and Bacteria. Eight- to 10-wk-old specific pathogen-free BALB/c and
C57BL/6 mice were purchased from Taconic Farms. TLR2−/− animals were
purchased from Jackson Laboratories. Mice were colonized with strains of
B. fragilis NCTC9343 and verified for proper colonization by plating under
aerobic and anaerobic conditions and PCR of fecal samples with primers
specific for B. fragilis and 16S rRNA bacterial primers. PSA was purified as
previously described for all treatment experiments (15). All animals were
cared for by approved Institutional Animal Care and Use Committee
guidelines from the California Institute of Technology.
In Vitro Suppression Assay. Either CD4+CD25+ or CD4+Foxp3+ cells were used
as a source of Tregs. CD4+CD25− cells were pulsed with 1 μL of a 5 μM CFSE
stock for 10 min at 37 °C. CFSE labeled cells were washed in PBS twice
and immediately used. 1 × 105 mitomycin C (Sigma)-treated CD4-depleted
splenocytes were mixed with CFSE-pulsed CD4+CD25− (or Foxp3−) respon-
der cells. Indicated dilutions of CD4+CD25+ Treg cells were titrated in and
1 μg/mL of anti-CD3 was added in a round bottom 96-well plate. Cultures
were incubated for 3 to 5 d and then analyzed by flow cytometry.
Experimental Colitis. Eight-week-old BALB/c mice were purchased from
Taconic Farms. For prophylactic studies, animals were pretreated with 50 μg
of PSA every other day for 6 d before administration of TNBS and every
other day after TNBS induction until necropsy. For curing studies, animals
were treated with a single dose of 50 μg of PSA 1 or 2 d following TNBS and
every other day until necropsy. See SI Materials and Methods for details.
Statistics. Differences between data sets were analyzed by Mann-Whitney
U test or student’s t test where applicable, and analyzed using GraphPad
Prism 5.0 or Microsoft Excel software.
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